Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes

OBJECTIVE To assess glucose-lowering mechanisms of sitagliptin (S), metformin (M), and the two combined (M+S). RESEARCH DESIGN AND METHODS We randomized 16 patients with type 2 diabetes mellitus (T2DM) to four 6-week treatments with placebo (P), M, S, and M+S. After each period, subjects received a 6-h meal tolerance test (MTT) with [14C]glucose to calculate glucose kinetics. Fasting plasma glucose (FPG), fasting plasma insulin, C-peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide (GIP) were measured. RESULTS FPG decreased from P, 160 ± 4 to M, 150 ± 4; S, 154 ± 4; and M+S, 125 ± 3 mg/dL. Mean post-MTT plasma glucose decreased from P, 207 ± 5 to M, 191 ± 4; S, 195 ± 4; and M+S, 161 ± 3 mg/dL (P < 0.01). The increase in mean post-MTT plasma insulin and in ISR was similar in P, M, and S and slightly greater in M+S. Fasting plasma glucagon was equal (∼65–75 pg/mL) with all treatments, but there was a significant drop during the initial 120 min with S 24% and M+S 34% (both P < 0.05) vs. P 17% and M 16%. Fasting and mean post-MTT plasma bioactive GLP-1 were higher (P < 0.01) after S and M+S vs. M and P. Basal endogenous glucose production (EGP) fell from P 2.0 ± 0.1 to S 1.8 ± 0.1 mg/kg ⋅ min, M 1.8 ± 0.2 mg/kg ⋅ min (both P < 0.05 vs. P), and M+S 1.5 ± 0.1 mg/kg ⋅ min (P < 0.01 vs. P). Although the EGP slope of decline was faster in M and M+S vs. S, all had comparable greater post-MTT EGP inhibition vs. P (P < 0.05). CONCLUSIONS M+S combined produce additive effects to 1) reduce FPG and postmeal plasma glucose, 2) augment GLP-1 secretion and β-cell function, 3) decrease plasma glucagon, and 4) inhibit fasting and postmeal EGP compared with M or S monotherapy.

[1]  A. Avogaro,et al.  The increased dipeptidyl peptidase‐4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin‐treated patients , 2012, Diabetes, obesity & metabolism.

[2]  R. DeFronzo,et al.  Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. , 2011, The Journal of clinical endocrinology and metabolism.

[3]  M. Matsuda,et al.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. , 1999, Diabetes care.

[4]  L. Disilvio,et al.  Impact of glucose ingestion on hepatic and peripheral glucose metabolism in man: an analysis based on simultaneous use of the forearm and double isotope techniques. , 1986, The Journal of clinical endocrinology and metabolism.

[5]  N. Irwin,et al.  Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. , 2006, European journal of pharmacology.

[6]  J. Leahy Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes , 2008 .

[7]  M. Nauck,et al.  Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial , 2007, Diabetes, obesity & metabolism.

[8]  J. Holst,et al.  The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. , 2007, The Journal of clinical endocrinology and metabolism.

[9]  J. Holst,et al.  Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. , 2010, The Journal of clinical endocrinology and metabolism.

[10]  J. Holst,et al.  GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes , 2011, Diabetes.

[11]  E. Mannucci,et al.  Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus , 2005, Diabetologia.

[12]  R. DeFronzo,et al.  Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. , 1996, The Journal of clinical endocrinology and metabolism.

[13]  J. Holst,et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.

[14]  E. Mannucci,et al.  Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. , 2001, Diabetes care.

[15]  Jeppe Sturis,et al.  Estimation of Insulin Secretion Rates from C-Peptide Levels: Comparison of Individual and Standard Kinetic Parameters for C-Peptide Clearance , 1992, Diabetes.

[16]  B. Braun,et al.  Combining short-term metformin treatment and one bout of exercise does not increase insulin action in insulin-resistant individuals. , 2010, American journal of physiology. Endocrinology and metabolism.

[17]  R. DeFronzo,et al.  Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. , 2008, American journal of physiology. Endocrinology and metabolism.

[18]  P. Flatt,et al.  Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[19]  B. Ahrén Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties , 2006, Expert opinion on investigational drugs.

[20]  R. Steele,et al.  Glucose Uptake and Production During the Oral Glucose Tolerance Test , 1968, Diabetes.

[21]  R. Hovorka,et al.  ISEC: a program to calculate insulin secretion. , 1996, Computer methods and programs in biomedicine.

[22]  J. Lenhard,et al.  Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. , 2004, Biochemical and biophysical research communications.

[23]  S. Mudaliar,et al.  The incretin hormones: from scientific discovery to practical therapeutics , 2012, Diabetologia.

[24]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[25]  C. Deacon Therapeutic strategies based on glucagon-like peptide 1. , 2004, Diabetes.